-
Asieris Pharmaceuticals Receives NMPA Approval for Hexvix (APL-1706) in Bladder Cancer Diagnosis
•
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that the National Medical Products Administration (NMPA) has approved a marketing filing for its product Hexvix (APL-1706), which is used in the diagnosis and management of bladder cancer. Product Approval and ImpactThe approval of Hexvix by the NMPA marks a…
-
Asieris Pharmaceuticals Gets FDA Green Light for USP1 Inhibitor APL-2302 in Advanced Solid Tumors
•
Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it has received clinical clearance from the U.S. Food and Drug Administration (FDA) for its in-house developed ubiquitin specific peptidase 1 (USP1) inhibitor, APL-2302, for the treatment of advanced solid tumors. Preclinical studies have indicated that…
-
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
•
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176), has reported a staggering year-on-year (YOY) increase of 103,397.96% in its 2024H1 financial report, with revenues reaching RMB 80.4934 million. The second quarter of the year saw even more impressive growth, achieving RMB 56.1739 million,…
-
Asieris Pharmaceuticals Gets NMPA Green Light for APL-1202 Clinical Trial in FLA Infections
•
Asieris Pharmaceuticals (SHA: 688176), a Chinese specialist in urogenital cancer, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate APL-1202 for the treatment of free-living amoebae (FLA) infections. APL-1202, an oral MetAP2 inhibitor, is currently in a Phase III…
-
NMPA Accepts Jiangsu Yahong Meditech’s Application for Cervical HSIL Treatment Cevira
•
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments in China, has announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for Cevira (APL-1702) for the treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix, excluding in…
-
Jiangsu Yahong Meditech to Present Phase III Results for Cervical Cancer Treatment at SGO Annual Meeting
•
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, is preparing to unveil key findings from a global multicenter Phase III clinical study on its Cevira (APL-1702) at the Society of Gynecologic Oncology (SGO) annual meeting. The study focuses on the treatment of high-grade squamous…
-
Asieris Pharmaceuticals Gets Australian Greenlight for Acinetobacter Infection Drug Trial
•
Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has received approval in Australia to commence a Phase I clinical study for its drug candidate APL-2301 (MET-102, formerly ASN-1733), which targets Acinetobacter baumannii infections. The study will evaluate the safety, tolerability, and pharmacokinetics of APL-2301 in healthy subjects…
-
Asieris Pharmaceuticals’ Hexvix for Bladder Cancer Accepted for Review by China’s NMPA
•
Asieris Pharmaceuticals (SHA: 688176), a specialist in urogenital cancer based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for its Hexvix (APL-1706) for the diagnosis and management of bladder cancer. Hexvix stands as the only globally approved agent…
-
Asieris Pharma Launches Generic Votrient for Renal Cell Carcinoma in China
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd, trading as Asieris Pharma (SHA: 688176), has announced the issuance of the first prescription for its generic version of the UK pharmaceutical major GSK’s (NYSE: GSK) Votrient (pazopanib) in China. This milestone not only marks the entry of a new treatment…
-
Jiangsu Yahong’s Cevira Meets Primary Endpoint in Phase III Cervical HSIL Study
•
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, has announced that its Phase III clinical study for Cevira (APL-1702) in high-grade squamous intraepithelial lesions (HSIL) of the cervix has successfully reached its primary endpoint. Study Design and ResultsThe global, multi-center Phase III study was…
-
Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab
•
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase II interim analysis of its drug candidate APL-1202, combined with BeiGene Ltd’s (NASDAQ: BGNE; HKG: 6160) programmed death-1 (PD-1) inhibitor tislelizumab, as neoadjuvant chemotherapy (NAC) in muscular invasive bladder cancer (MIBC). The trial has demonstrated…
